# TL Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tl-genomics

- Industry: Biotechnology
- Headquarters: Fujisawa, Japan
- Website: www.tlgenomics.com
- Total disclosed funding: $3.5M
- Latest round: Series B (May 7, 2018)
- Investors on record: 3

## About

Founded in 2015 and located in Kanagawa, Japan, TL Genomics Inc. specializes in the creation and distribution of tests and diagnostic agents pertinent to bone marrow transplantation, assessments of disease risk through chromosome analysis, fertility testing, and various other medical care services. In March 2026, TL Genomics Inc. raised an undisclosed amount in?venture funding from Meinan Management Capital and Shizuoka Prefecture. The round was part of a larger venture and grant funding.

TL Genomics Inc. specializes in innovative biotechnology solutions aimed at age-related health assessments and diagnostics. The company's core offerings include a groundbreaking biological age assessment service utilizing advanced PCR-based chromosome testing technology branded as SinChro™. This technology enables the measurement and estimation of biological markers, providing insights into an individual’s aging process. Additionally, TL Genomics is dedicated to developing in vitro diagnostic products to detect chromosomal abnormalities associated with myelodysplastic syndromes. These services cater to healthcare providers and personal consumers primarily in Japan, with aspirations for broader international market engagement as the technology matures.The revenue model of TL Genomics Inc. is predicated on direct-to-consumer and B2B transactions for its diagnostic services. The company offers its biological age assessment and chromosome testing services through a straightforward transactional structure, where customers can access these services on a per-test basis. The flagship SinChro™ assessment is marketed to both individual clients seeking personal health insights and healthcare institutions looking to incorporate advanced diagnostics into their offerings. This dual approach allows for diverse revenue streams while fostering partnerships within the healthcare sector, thereby establishing a comprehensive ecosystem for its innovative products.

The company plans to use the March 2026 funding to create domestically manufactured testing kit known as the Chimerism Test and to establish a manufacturing facility in eastern Shizuoka.

## Funding rounds

- Series B, May 7, 2018, $2.8M — SMBC Venture Capital, Nissay Capital, DBJ Capital
- Series A, Nov 18, 2016, $0.7M — Nissay Capital

## Investors

- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series A, Series B
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series B
- DBJ Capital (https://capitalatlas.ai/funds/dbj-capital) — Series B